A gut bacterium and its metabolite extend healthspan in aged mice

A study published in Nature Aging on 25 August 2026 names a specific gut bacterium and a specific molecule it makes as candidate geroprotectors, and tests both.

The authors, working across several Chinese institutions, built a microbiome-based aging clock they call MicroAge and found that Bifidobacterium pseudocatenulatum is consistently depleted during aging in both sexes in the Chinese populations studied. They then gave the bacterium to aged mice. It rescued intestinal homeostasis, mitigated multiorgan inflammaging, improved cognitive and motor performance, and extended healthspan. Giving the mice the bacterial metabolite alone, 5-aminovaleric acid betaine or 5-AVAB, partially reproduced that spread of systemic benefits.

Two limits are worth stating plainly. The intervention arm is mice, and the human component is an association between the abundance of an organism and a measure of biological age, not a trial. And the claim is healthspan, not lifespan: the mice were reported as functioning better in old age, which is a different result from living longer.

The identification of a single metabolite is the part that travels. A bacterium has to be kept alive to be a therapy, whereas a molecule can be dosed.